Pnd59 - Cost Effectiveness Analysis of Alemtuzumab as a Treatment Option for Patients With Multiple Sclerosis in Greece

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pnd66 - Cost Effectiveness Analysis of Alemtuzumab as a Treatment Option for Patients With Multiple Sclerosis in Cyprus

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

A Case of Autoimmune Myositis After Treatment With Alemtuzumab for Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2018English

Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England

Journal of Medical Economics
Health Policy
2018English

Pnd57 - The Cost-Effectiveness of Alemtuzumab in the Management of Relapse-Remitting Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Immune Competence After Alemtuzumab Treatment of Multiple Sclerosis

Neurology
Neurology
2013English

Adverse Events With Fatal Outcome Associated With Alemtuzumab Treatment in Multiple Sclerosis

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2019English

Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy